| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86a89d8fa590056286e0bf7f1ae2a3e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e5c121269689cbab9b3a4548b15caf3 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2017-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_633a212b72e1cf24e2f03ca74880cd71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77b921b43d081ab215d65aa73d8242bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba5427b39a2188c7cd805c13e9490559
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59d8129e7d5a476902752d2e34e96b80 |
| publicationDate |
2020-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2020055750-A |
| titleOfInvention |
Nucleic acid drugs that inhibit cancer invasion or metastasis |
| abstract |
An object of the present invention is to provide an antitumor agent effective for a tumor having invasive or metastatic potential. The present invention discloses an antitumor agent containing a SNORA23 gene expression inhibitor. The SNORA23 expression inhibitor has a nucleoside structure represented by the following formula (I): Embedded image (Wherein Base and A are predetermined substituents or structures) or a pharmacologically acceptable salt thereof. An antitumor agent comprising a SYNE2 gene expression inhibitor is also disclosed. [Selection diagram] None |
| priorityDate |
2017-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |